Video

How Can Specialty Pharmacies Impact Lung Cancer Outcomes?

Donna M. Smith, PharmD, director of clinical affairs at Avella Specialty Pharmacy discusses how specialty pharmacists can help manage difficult lung cancer therapy.

Donna M. Smith, PharmD, director of clinical affairs at Avella Specialty Pharmacy discusses how specialty pharmacists can help manage difficult lung cancer therapy.

This video was shot at the Armada Health Care 2014 Specialty Pharmacy Summit and Expo in Las Vegas, Nevada.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com
Austin Texas | Image credit: Kevin Ruck - stock.adobe.com
Related Content
Cardiomyopathy (ATTR-CM) -- Image credit: Dzmitry | stock.adobe.com
July 1st 2025

Pharmacists Have a Crucial Role Helping Patients With ATTR-CM Navigate Treatment With Tafamidis

Gillian McGovern, Associate Editor Jennifer Goldman, PharmD, CDES, BC-ADM, FCCP
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
Group of women holding breast cancer ribbon | Image Credit: © Rawpixel.com - stock.adobe.com
July 1st 2025

Study Reveals Alarming Gaps in HER2 Therapy Access for Patients With Breast Cancer

Alexandra Gerlach, Associate Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Visualization of pulmonary hypertension | Image Credit: © Thirawat - stock.adobe.com
June 30th 2025

Pulmonary Hypertension Associated With Increased Risk of Progression in Patients With Myeloproliferative Neoplasms

Alexandra Gerlach, Associate Editor
Illustration of bone marrow fibrosis | Image Credit: © AImmersive Imagery - stock.adobe.com
June 30th 2025

Ropeginterferon Alfa 2b Is Well-Tolerated, Efficacious in Treatment of Prefibrotic Myelofibrosis

Alexandra Gerlach, Associate Editor